Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference
06 févr. 2023 16h05 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director
26 janv. 2023 16h05 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its board of...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium
17 janv. 2023 16h05 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates
10 nov. 2022 16h05 HE | Kinnate Biopharma
Cash, cash equivalents and investments of $262.1 million as of September 30, 2022; cash runway expected to fund operations into mid-2024 SAN FRANCISCO and SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE)...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Announces Recent Corporate Updates, Including on the Ongoing KIN-2787 Monotherapy Dose Escalation from Global Phase 1 Trial
11 oct. 2022 16h05 HE | Kinnate Biopharma
KIN-2787 cleared the predicted efficacious dose at 300 mg bid; dose escalation continues with maximum tolerated dose not yet determined KIN-2787 achieved meaningful exposures that were dose...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-2787, an Investigational Pan-RAF Inhibitor
21 sept. 2022 16h05 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the U.S. Food and...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Participate in the 2022 Piper Sandler Heartland Summit
15 sept. 2022 16h05 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Participate in the 2022 Wells Fargo Securities Healthcare Conference
30 août 2022 16h05 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. Announces Second Quarter 2022 Financial Results and Recent Corporate Updates
11 août 2022 16h05 HE | Kinnate Biopharma
Phase 1 clinical trial for KIN-2787, the company’s investigational pan-RAF inhibitor, was initiated in Taiwan by Kinnjiu Biopharma Inc., Kinnate’s China joint ventureU.S. Food and Drug Administration...
Kinnate_LogoColor@10x.png
Kinnate Biopharma Inc. to Participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference
02 août 2022 16h05 HE | Kinnate Biopharma
SAN FRANCISCO and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its chief...